| CEO |
Seng-ho Jeon |
- Head of Global Strategy Team, Daewoong Pharmaceutical
- Head of Global Business Division,
Daewoong Pharmaceutical
|
Mar 2018 |
Mar 2024 |
Registered |
| Chang-jae Lee |
- Head of ETC Division,
Daewoong Pharmaceutical
- Head of Marketing Division,
Daewoong Pharmaceutical
- Executive Director, Daewoong
|
Jan 2022 |
Mar 2024 |
Registered |
| Executive Director |
Seongsoo Park |
- College of Pharmacy, Seoul National University, Korea
- Medicinal Chemistry Master of Science (MS), Seoul National Univesity
- Head of Daewoong America, Inc.
- Head of Nabota Business Division / Executive Director (Current)
- Executive Vice President (Current)
|
Mar 2023 |
Mar 2026 |
Registered |
| Outside Director |
Hong-cheol Kim |
- Director, Corporate Research
- Outside Director, Hanall Biopharma
- Auditor, Bridge Biotherapeutics
|
Mar 2018 |
Mar 2024 |
Registered |
| Dae-duk Kim |
- Director, Research center for endogenous ligand signal transduction modulation anticancer agent(MRC)
- President of Korean Society of Pharmaceutical Sciences and Technology (KSPST) (2018)
- Professor of College of Pharmacy,
Seoul National University,
Korea (Current)
- Fellow member of Korea Academy of Science and Technology (Current)
|
Mar 2022 |
Mar 2025 |
Registered |
| Yong-Jin Kim |
- College of Medicine, Seoul National University, Korea
- MD-Ph.D of Internal Medicine, Seoul National University
- Director of Research Institute / R&DB Foundation, Seoul National University
- Director of Planning Office, Seoul National University
- Professor of Internal Medicine, Seoul National University (Current)
|
Mar 2023 |
Mar 2026 |
Registered |